Analyst firms · Cantor Fitzgerald · REPL

Cantor Fitzgerald REPL price target and rating history

Replimune Group Inc. (REPL) · Health Care

Cantor Fitzgerald rates Replimune Group Inc. (REPL) Overweight, as of its latest action on Jul 31, 2026. It has published 3 rating actions on REPL since June 2025, including 2 upgrades and 0 downgrades. Across 5 firms with a REPL price target in the last 12 months, the median target is $12.

Current rating
Overweight
Price target
Not stated
Median target, all firms
$12
Actions on REPL
3

Every Cantor Fitzgerald rating on REPL

How other firms rate REPL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
WedbushOutperform$12Aug 7, 2026
Leerink PartnersOutperform$17Aug 4, 2026
Cantor FitzgeraldOverweightJul 31, 2026
BMO Capital MarketsOutperform$16Jun 30, 2026
JefferiesHold$2Apr 13, 2026
H.C. WainwrightSellApr 13, 2026
Piper SandlerNeutral$4Apr 10, 2026

Questions about Cantor Fitzgerald and REPL

What is Cantor Fitzgerald's rating on REPL?
Cantor Fitzgerald rates REPL Overweight, a bullish rating, as of Jul 31, 2026.
When did Cantor Fitzgerald last change its view on REPL?
On Jul 31, 2026, Cantor Fitzgerald upgrades to Overweight from Neutral.
How does Cantor Fitzgerald's REPL target compare with other analysts?
Across 5 firms with a REPL price target in the last 12 months, the median target is $12.

More REPL rating histories

All Cantor Fitzgerald ratingsREPL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.